Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse

Neurology

Volumn 74, Issue 21, 2010, Pages 1687-1693

  Taes, I ^a,b   Goris, A ^a   Lemmens, R ^a,b   Van Es, M A ^c   Van Den Berg, L H ^c   Chio, A ^d   Traynor, B J ^e   Birve, A ^f   Andersen, P ^f   Slowik, A ^g   Tomik, B ^g   Brown, R H ^h   Shaw, C E ⁱ   Al Chalabi, A ⁱ   Boonen, S ^a   Van Den Bosch, L ^a,b   Dubois, B ^a   Van Damme, P ^a,b   Robberecht, W ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF TURIN   (Italy)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g JAGIELLONIAN UNIVERSITY   (Poland)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 77952986361     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e042f7     Document Type: Article

References (35)

1. Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998;95:13103-13107.
2. Hutton M, Lendon CL, Rizzu P, et al. Association of mis-sense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
3. Nasreddine ZS, Loginov M, Clark LN, et al. From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Ann Neurol 1999;45:704-715.
4. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-715. (Pubitemid 29139987)
5. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005;42:837-846.
6. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005;14:3281-3292.
7. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706.
8. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62:145-153.
9. Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 2007;62:137-144.
10. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316: 750-754.
11. Myers AJ, Gibbs JR, Webster JA, et al. A survey of genetic human cortical gene expression. Nat Genet 2007;39: 1494-1499.
12. Llado A, Ezquerra M, Gaig C, Sanchez-Valle R, Tolosa E, Molinuevo JL. Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. J Neural Transm 2007;114:1585-1588.
13. Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologi-cally normal controls: first stage analysis and public release of data. Lancet Neurol 2007;6:322-328.
14. van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007; 6:869-877.
15. Stefansson H, Helgason A, Thorleifsson G, et al. A common inversion under selection in Europeans. Nat Genet 2005;37:129-137.
16. Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neuro-sci 2001;4:29-37.
17. Van Damme P, Braeken D, Callewaert G, Robberecht W, Van Den Bosch L. GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005;64:605-612.
18. Russ C, Powell JF, Zhao J, et al. The microtubule associated protein Tau gene and Alzheimer's disease: an association study and meta-analysis. Neurosci Lett 2001;314:92-96. (Pubitemid 33043812)
19. Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet 2007;8:3.
20. Myers AJ, Kaleem M, Marlowe L, et al. The H1c haplo-type at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005;14:2399-2404.
21. Laws SM, Friedrich P, Diehl-Schmid J, et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol Psychiatry 2007;12:510-517.
22. Verpillat P, Camuzat A, Hannequin D, et al. Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol 2002;59:935-939.
23. Johansson A, Zetterberg H, Hakansson A, Nissbrandt H, Blennow K. Tau haplotype and the Saitohin Q7R gene polymorphism do not influence CSF tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. Neurodegen Dis 2005;2:28-35.
24. Bernardi L, Maletta RG, Tomaino C, et al. The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol Aging 2006;27:702-709.
25. Laws SM, Friedrich P, Diehl-Schmid J, et al. Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol Aging 2008;29:1276-1278.
26. Munch C, Prechter F, Xu R, et al. Frequency of a tau genotype in amyotrophic lateral sclerosis. J Neurol Sci 2005;236:13-16.
27. Poorkaj P, Tsuang D, Wijsman E, et al. TAU as a susceptibility gene for amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Arch Neurol 2001;58:1871-1878.
28. Sundar PD, Yu CE, Sieh W, et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum Mol Genet 2007;16:295-306.
29. Laws SM, Perneczky R, Drzezga A, et al. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. Am J Psychiatry 2007;164:1577-1584.
30. Borroni B, Yancopoulou D, Tsutsui M, et al. Association between tau H2 haplotype and age at onset in frontotem-poral dementia. Arch Neurol 2005;62:1419-1422.
31. Kobayashi H, Ujike H, Hasegawa J, Yamamoto M, Kan-zaki A, Sora I. Correlation of tau gene polymorphism with age at onset of Parkinson's disease. Neurosci Lett 2006; 405:202-206.
32. Sleegers K, Brouwers N, Maurer-Stroh S, et al. Progranu-lin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 2008;71:253-259.
33. Van Damme P, Bogaert E, Dewil M, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci USA 2007; 104:14825-14830.
34. Van Damme P, Leyssen M, Callewaert G, Robberecht W, Van Den Bosch L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotro-phic lateral sclerosis. Neurosci Lett 2003;343:81-84.
35. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyo-trophic lateral sclerosis. Biochim Biophys Acta 2006;1762: 1068-1082.